PACAP and PAC1 Receptor Expression in Human Insulinomas

• DOI: 10.1007/s10989-021-10204-0
• Publication Date: 2021-04-09T08:06:55Z
• Authors: Sandor Ferencz; Denes Toth; Balint Kaszas; Sebastian Bardosi; Viktoria Vicena; Oszkar Karadi; Dora Reglodi; Dezso Kelemen
• Keywords: 0303 health sciences; 03 medical and health sciences; neurológia; RA1001 Forensic Medicine. Medical jurisprudence. Legal medicine / igazságügyi-; pszichiátria; RD Surgery / sebészet; törvényszéki orvostan; RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry / idegkórtan

AbstractPituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with widespread occurrence and diverse functions. PACAP binds to specific PAC1 and non-specific VPAC1/2 receptors. PACAP is considered as a growth factor, as it plays important roles during development and participates in reparative processes. Highest concentrations are found in the nervous system and endocrine glands, where several functions are known, including actions in tissue growth, differentiation and tumour development. Therefore, we have investigated expression of PACAP and its receptors in different tumours, including those of endocrine glands. We showed earlier that PACAP and PAC1 receptor staining intensity decreased in pancreatic ductal adenocarcinoma. In the present study we aimed to investigate alterations of PACAP and PAC1 receptor in human insulinoma and compared the immunostaining pattern with samples from chronic pancreatitis patients. We collected perioperative and histological data of patients who underwent operation because of insulinoma or chronic pancreatitis over a five-year-long period. Histology showed chronic pancreatitis with severe scar formation in pancreatitis patients, while tumour samples evidenced Grade 1 or 2 insulinoma. PACAP and PAC1 receptor expression was studied using immunohistochemistry. Staining intensity was very strong in the Langerhans islets of normal tissue and discernible staining was also observed in the exocrine pancreas. Immunostaining intensity for both PACAP and PAC1 receptor was markedly weaker in insulinoma samples, and disappeared from chronic pancreatitis samples except for intact islets. These findings show that PAC1 receptor/PACAP signalling is altered in insulinoma and this suggests a possible involvement of this system in tumour growth or differentiation.